Global AI In Clinical Trials 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI06254087

Publication Date:

June 20, 2025

Pages:

150

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global AI In Clinical Trials market size is predicted to grow from US$ 54.3 million in 2025 to US$ 81.8 million in 2031; it is expected to grow at a CAGR of 7.1% from 2025 to 2031.
The AI in Clinical Trials market is experiencing significant growth and is expected to continue to expand in the coming years. AI, or artificial intelligence, is being increasingly utilized in the field of clinical trials to enhance various aspects of the trial process, including patient recruitment, data analysis, and drug development.One major trend in the AI in Clinical Trials market is the use of machine learning algorithms to improve patient recruitment and retention. AI algorithms can analyze large amounts of patient data and identify potential candidates for clinical trials more efficiently and accurately than traditional methods. This can help accelerate the recruitment process and ensure that trials have a diverse and representative patient population.
The 鈥淎I In Clinical Trials Industry Forecast鈥� looks at past sales and reviews total world AI In Clinical Trials sales in 2024, providing a comprehensive analysis by region and market sector of projected AI In Clinical Trials sales for 2025 through 2031. With AI In Clinical Trials sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world AI In Clinical Trials industry.
This Insight Report provides a comprehensive analysis of the global AI In Clinical Trials landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on AI In Clinical Trials portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global AI In Clinical Trials market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for AI In Clinical Trials and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global AI In Clinical Trials.
This report presents a comprehensive overview, market shares, and growth opportunities of AI In Clinical Trials market by product type, application, key players and key regions and countries.
Segmentation by Type:
Software
Service
Segmentation by Application:
Pharmaceutical and Biotechnology Companies
Contract Research Organization
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Intel
The International Business Machines Corporation(IBM)
Koninklijke Philips N.V.
ConcertAl
Saama Technologies LLC
Samaa Technologies
Owkin Inc.
Numerate
Neuroute
AiCure
Ardigen
Unlearn Al
PathAl
Exscentia
Aitia Infotech Pvt Ltd.
Euretos
VeriSIM Life
Envisagenics
NURITAs
BioSymetrics
BioAge Labs lInc

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global AI In Clinical Trials 麻豆原创 Size (2020-2031)
2.1.2 AI In Clinical Trials 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for AI In Clinical Trials by Country/Region (2020, 2024 & 2031)
2.2 AI In Clinical Trials Segment by Type
2.2.1 Software
2.2.2 Service
2.3 AI In Clinical Trials 麻豆原创 Size by Type
2.3.1 AI In Clinical Trials 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global AI In Clinical Trials 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 AI In Clinical Trials Segment by Application
2.4.1 Pharmaceutical and Biotechnology Companies
2.4.2 Contract Research Organization
2.4.3 Other
2.5 AI In Clinical Trials 麻豆原创 Size by Application
2.5.1 AI In Clinical Trials 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global AI In Clinical Trials 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 AI In Clinical Trials 麻豆原创 Size by Player
3.1 AI In Clinical Trials 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global AI In Clinical Trials Revenue by Player (2020-2025)
3.1.2 Global AI In Clinical Trials Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global AI In Clinical Trials Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 AI In Clinical Trials by Region
4.1 AI In Clinical Trials 麻豆原创 Size by Region (2020-2025)
4.2 Global AI In Clinical Trials Annual Revenue by Country/Region (2020-2025)
4.3 Americas AI In Clinical Trials 麻豆原创 Size Growth (2020-2025)
4.4 APAC AI In Clinical Trials 麻豆原创 Size Growth (2020-2025)
4.5 Europe AI In Clinical Trials 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa AI In Clinical Trials 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas AI In Clinical Trials 麻豆原创 Size by Country (2020-2025)
5.2 Americas AI In Clinical Trials 麻豆原创 Size by Type (2020-2025)
5.3 Americas AI In Clinical Trials 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC AI In Clinical Trials 麻豆原创 Size by Region (2020-2025)
6.2 APAC AI In Clinical Trials 麻豆原创 Size by Type (2020-2025)
6.3 APAC AI In Clinical Trials 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe AI In Clinical Trials 麻豆原创 Size by Country (2020-2025)
7.2 Europe AI In Clinical Trials 麻豆原创 Size by Type (2020-2025)
7.3 Europe AI In Clinical Trials 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa AI In Clinical Trials by Region (2020-2025)
8.2 Middle East & Africa AI In Clinical Trials 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa AI In Clinical Trials 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global AI In Clinical Trials 麻豆原创 Forecast
10.1 Global AI In Clinical Trials Forecast by Region (2026-2031)
10.1.1 Global AI In Clinical Trials Forecast by Region (2026-2031)
10.1.2 Americas AI In Clinical Trials Forecast
10.1.3 APAC AI In Clinical Trials Forecast
10.1.4 Europe AI In Clinical Trials Forecast
10.1.5 Middle East & Africa AI In Clinical Trials Forecast
10.2 Americas AI In Clinical Trials Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 AI In Clinical Trials Forecast
10.2.2 Canada 麻豆原创 AI In Clinical Trials Forecast
10.2.3 Mexico 麻豆原创 AI In Clinical Trials Forecast
10.2.4 Brazil 麻豆原创 AI In Clinical Trials Forecast
10.3 APAC AI In Clinical Trials Forecast by Region (2026-2031)
10.3.1 China AI In Clinical Trials 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 AI In Clinical Trials Forecast
10.3.3 Korea 麻豆原创 AI In Clinical Trials Forecast
10.3.4 Southeast Asia 麻豆原创 AI In Clinical Trials Forecast
10.3.5 India 麻豆原创 AI In Clinical Trials Forecast
10.3.6 Australia 麻豆原创 AI In Clinical Trials Forecast
10.4 Europe AI In Clinical Trials Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 AI In Clinical Trials Forecast
10.4.2 France 麻豆原创 AI In Clinical Trials Forecast
10.4.3 UK 麻豆原创 AI In Clinical Trials Forecast
10.4.4 Italy 麻豆原创 AI In Clinical Trials Forecast
10.4.5 Russia 麻豆原创 AI In Clinical Trials Forecast
10.5 Middle East & Africa AI In Clinical Trials Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 AI In Clinical Trials Forecast
10.5.2 South Africa 麻豆原创 AI In Clinical Trials Forecast
10.5.3 Israel 麻豆原创 AI In Clinical Trials Forecast
10.5.4 Turkey 麻豆原创 AI In Clinical Trials Forecast
10.6 Global AI In Clinical Trials Forecast by Type (2026-2031)
10.7 Global AI In Clinical Trials Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 AI In Clinical Trials Forecast
11 Key Players Analysis
11.1 Intel
11.1.1 Intel Company Information
11.1.2 Intel AI In Clinical Trials Product Offered
11.1.3 Intel AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Intel Main Business Overview
11.1.5 Intel Latest Developments
11.2 The International Business Machines Corporation(IBM)
11.2.1 The International Business Machines Corporation(IBM) Company Information
11.2.2 The International Business Machines Corporation(IBM) AI In Clinical Trials Product Offered
11.2.3 The International Business Machines Corporation(IBM) AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 The International Business Machines Corporation(IBM) Main Business Overview
11.2.5 The International Business Machines Corporation(IBM) Latest Developments
11.3 Koninklijke Philips N.V.
11.3.1 Koninklijke Philips N.V. Company Information
11.3.2 Koninklijke Philips N.V. AI In Clinical Trials Product Offered
11.3.3 Koninklijke Philips N.V. AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Koninklijke Philips N.V. Main Business Overview
11.3.5 Koninklijke Philips N.V. Latest Developments
11.4 ConcertAl
11.4.1 ConcertAl Company Information
11.4.2 ConcertAl AI In Clinical Trials Product Offered
11.4.3 ConcertAl AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 ConcertAl Main Business Overview
11.4.5 ConcertAl Latest Developments
11.5 Saama Technologies LLC
11.5.1 Saama Technologies LLC Company Information
11.5.2 Saama Technologies LLC AI In Clinical Trials Product Offered
11.5.3 Saama Technologies LLC AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Saama Technologies LLC Main Business Overview
11.5.5 Saama Technologies LLC Latest Developments
11.6 Samaa Technologies
11.6.1 Samaa Technologies Company Information
11.6.2 Samaa Technologies AI In Clinical Trials Product Offered
11.6.3 Samaa Technologies AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Samaa Technologies Main Business Overview
11.6.5 Samaa Technologies Latest Developments
11.7 Owkin Inc.
11.7.1 Owkin Inc. Company Information
11.7.2 Owkin Inc. AI In Clinical Trials Product Offered
11.7.3 Owkin Inc. AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Owkin Inc. Main Business Overview
11.7.5 Owkin Inc. Latest Developments
11.8 Numerate
11.8.1 Numerate Company Information
11.8.2 Numerate AI In Clinical Trials Product Offered
11.8.3 Numerate AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Numerate Main Business Overview
11.8.5 Numerate Latest Developments
11.9 Neuroute
11.9.1 Neuroute Company Information
11.9.2 Neuroute AI In Clinical Trials Product Offered
11.9.3 Neuroute AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Neuroute Main Business Overview
11.9.5 Neuroute Latest Developments
11.10 AiCure
11.10.1 AiCure Company Information
11.10.2 AiCure AI In Clinical Trials Product Offered
11.10.3 AiCure AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 AiCure Main Business Overview
11.10.5 AiCure Latest Developments
11.11 Ardigen
11.11.1 Ardigen Company Information
11.11.2 Ardigen AI In Clinical Trials Product Offered
11.11.3 Ardigen AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Ardigen Main Business Overview
11.11.5 Ardigen Latest Developments
11.12 Unlearn Al
11.12.1 Unlearn Al Company Information
11.12.2 Unlearn Al AI In Clinical Trials Product Offered
11.12.3 Unlearn Al AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Unlearn Al Main Business Overview
11.12.5 Unlearn Al Latest Developments
11.13 PathAl
11.13.1 PathAl Company Information
11.13.2 PathAl AI In Clinical Trials Product Offered
11.13.3 PathAl AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 PathAl Main Business Overview
11.13.5 PathAl Latest Developments
11.14 Exscentia
11.14.1 Exscentia Company Information
11.14.2 Exscentia AI In Clinical Trials Product Offered
11.14.3 Exscentia AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Exscentia Main Business Overview
11.14.5 Exscentia Latest Developments
11.15 Aitia Infotech Pvt Ltd.
11.15.1 Aitia Infotech Pvt Ltd. Company Information
11.15.2 Aitia Infotech Pvt Ltd. AI In Clinical Trials Product Offered
11.15.3 Aitia Infotech Pvt Ltd. AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Aitia Infotech Pvt Ltd. Main Business Overview
11.15.5 Aitia Infotech Pvt Ltd. Latest Developments
11.16 Euretos
11.16.1 Euretos Company Information
11.16.2 Euretos AI In Clinical Trials Product Offered
11.16.3 Euretos AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Euretos Main Business Overview
11.16.5 Euretos Latest Developments
11.17 VeriSIM Life
11.17.1 VeriSIM Life Company Information
11.17.2 VeriSIM Life AI In Clinical Trials Product Offered
11.17.3 VeriSIM Life AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 VeriSIM Life Main Business Overview
11.17.5 VeriSIM Life Latest Developments
11.18 Envisagenics
11.18.1 Envisagenics Company Information
11.18.2 Envisagenics AI In Clinical Trials Product Offered
11.18.3 Envisagenics AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 Envisagenics Main Business Overview
11.18.5 Envisagenics Latest Developments
11.19 NURITAs
11.19.1 NURITAs Company Information
11.19.2 NURITAs AI In Clinical Trials Product Offered
11.19.3 NURITAs AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.19.4 NURITAs Main Business Overview
11.19.5 NURITAs Latest Developments
11.20 BioSymetrics
11.20.1 BioSymetrics Company Information
11.20.2 BioSymetrics AI In Clinical Trials Product Offered
11.20.3 BioSymetrics AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.20.4 BioSymetrics Main Business Overview
11.20.5 BioSymetrics Latest Developments
11.21 BioAge Labs lInc
11.21.1 BioAge Labs lInc Company Information
11.21.2 BioAge Labs lInc AI In Clinical Trials Product Offered
11.21.3 BioAge Labs lInc AI In Clinical Trials Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.21.4 BioAge Labs lInc Main Business Overview
11.21.5 BioAge Labs lInc Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.